Printed From BioPortfolio.com
FDA OKs Durvalumab for Reducing Risk for NSCLC Progression
13:54 EST 16 Feb 2018 | Medscape
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.
FDA Approvals
Original Article: FDA OKs Durvalumab for Reducing Risk for NSCLC Progression
